Independent Evolution of Human Immunodeficiency Virus (HIV) Drug Resistance Mutations in Diverse Areas of the Brain in HIV-Infected Patients, with and without Dementia, on Antiretroviral Treatment
Open Access
- 15 September 2004
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (18) , 10133-10148
- https://doi.org/10.1128/jvi.78.18.10133-10148.2004
Abstract
AIDS dementia complex (ADC) in human immunodeficiency virus (HIV)-infected patients continues to be a problem in the era of highly active antiretroviral therapy (HAART). A better understanding of the drug resistance mutation patterns that emerge in the central nervous system (CNS) during HAART is of paramount importance as these differences in drug resistance mutations may explain underlying reasons for poor penetration of antiretroviral drugs into the CNS and suboptimal concentrations of the drugs that may reside in the brains of HIV-infected individuals during therapy. Thus, we provide a detailed analysis of HIV type 1 (HIV-1) protease and reverse transcriptase (RT) genes derived from different regions of the brains of 20 HIV-1-infected patients (5 without ADC, 2 with probable ADC, and 13 with various stages of ADC) on antiretroviral therapy. We show the compartmentalization and independent evolution of both primary and secondary drug resistance mutations to both RT and protease inhibitors in diverse regions of the CNS of HIV-infected patients, with and without dementia, on antiretroviral therapy. Our results suggest that the independent evolution of drug resistance mutations in diverse areas of the CNS may emerge as a consequence of incomplete suppression of HIV, probably related to suboptimal drug levels in the CNS and drug selection pressure. The emergence of resistant virus in the CNS may have considerable influence on the outcome of neurologic disease and also the reseeding of HIV in the systemic circulation upon failure of therapy.Keywords
This publication has 40 references indexed in Scilit:
- Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patientsAIDS, 2000
- Antiretroviral Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Protease from Paired Cerebrospinal Fluid and Plasma SamplesThe Journal of Infectious Diseases, 2000
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Short Communication: Unique HIV Type 1 V3 Region Sequences Derived from Six Different Regions of Brain: Region-Specific Evolution within Host-Determined QuasispeciesAIDS Research and Human Retroviruses, 1998
- Treating AIDS DementiaScience, 1997
- The Effect on Human Immunodeficiency Virus Type 1 RNA Levels in Cerebrospinal Fluid after Initiation of Zidovudine or DidanosineThe Journal of Infectious Diseases, 1997
- Distinct but Related Human Immunodeficiency Virus Type 1 Variant Populations in Genital Secretions and BloodAIDS Research and Human Retroviruses, 1996
- CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choiceNucleic Acids Research, 1994
- Counting phylogenetic invariants in some simple casesJournal of Theoretical Biology, 1991
- A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequencesJournal of Molecular Evolution, 1980